Daratumumab (DARZALEX) is recombinant IgG1k monoclonal antibody targeting CD38, which is an antigen uniformly expressed by plasma cells in multiple myeloma and light-chain amyloidosis (AL). On November 21, 2016, the U.S. Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

纯度：≥98%

CAS：945721-28-8